Genscript Biotech sees strong revenue, profit growth in interim report

Genscript Biotech Corporation reported a substantial increase in revenue from continuing operations, reaching $518.8m for the six months ended June 30, 2025, an 81.9% increase from the $285.2m reported in the prior period. This growth translated into a gross profit of $320.6m, a 140.1% increase. Adjusted net profit from continuing operations surged by 509.6% to $178.0m, up from $29.2m in the prior period.

The company's Biologics Development Services segment saw exceptional growth, with revenue increasing by 511.1% to $246.9m, largely due to a significant rise in license revenue from LaNova Medicines Ltd. This segment's adjusted gross profit increased to $181.6m, and it swung from an operating loss to an adjusted operating profit of $149.6m. Life-science Services and Products also contributed with $247.6m in revenue, an 11.3% increase.

Despite these gains, the Group recorded a net loss of $24.5m, significantly impacted by a $193.7m share of loss from its associate, Legend Group. As of June 30, 2025, cash and bank balances, along with wealth management financial products, totaled approximately $966.6m, providing ample resources for future operations and expansion.